The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
The Japanese group licenses sapablursen from Ionis for $280m.
The companies press on with vilastobart and IMPT-314... up to a point.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.